Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
NCT04991103
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Amyloidosis
Interventions
DRUG:
DaraVRD/DaraVCD
Sponsor
University of Alabama at Birmingham